Résumé
L’épidémie d’Ebola qui a sévit en Afrique de l’Ouest entre 2013 et 2016 a considérablement accéléré la recherche et le développement de vaccins Ebola. Plusieurs dizaines d’essais cliniques ont été conduits récemment et ont permis d’évaluer un certain nombre de nouveaux candidats vaccins. D’autres vaccins ne sont encore qu’à des phases précoces de développement (tableau 1). Cet article propose de donner un aperçu des avancées dans ce domaine.
Abstract
The Ebola epidemic that occurred in West Africa between 2013-2016 significantly accelerated the research and development of Ebola vaccines. Few dozens of clinical trials have been recently conducted leading to opportunities to test several new vaccine candidates. Other vaccines are still in early development phases (table 1). This paper provides an overview of the new developments in that area.
Références
Amante DH, Smith TR, Mendoza JM, et al (2015) Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device. Hum Gene Ther Methods 26(4):134–46
Beeching NJ, Fenech M, Houlihan CF (2014) Ebola virus disease. BMJ 349:g7348
Blaney JE, Marzi A, Willet M, et al (2013) Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 9(5):e1003389
Bukreyev AA, Dinapoli JM, Yang L, et al (2010) Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates respiratory tract of vector-immune monkeys and is immunogenic. Virology 399(2):290–8
Centers for Diseases Control and Prevention (2016) 2014 Ebola Outbreak in West Africa-Case Counts. [En ligne] [accédé le 11 juin 2016)
Deal C, Pekosz A, Ketner G (2013) Prospects for oral replicating adenovirus-vectored vaccines. Vaccine 31(32):3236–43
Ewer K1, Rampling T1, Venkatraman N, et al (2016) A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med 374(17):1635–46
Geisbert TW, Pushko P, Anderson K, et al (2002) Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 8(5):503–7
Halfmann P, Ebihara H, Marzi A, et al (2009) Replicationdeficient Ebolavirus as a vaccine candidate. J Virol 83(8):3810–5
Henao-Restrepo AM, Longini IM, Egger M, et al (2015) Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomized trial. Lancet 386(9996):857–66
Henao-Restrepo AM, Preziosi M-P, Wood D, et al (2016) On a path to accelerate access to Ebola vaccines: The WHO’s research and development efforts during the 2014-2016 Ebola epidemic in West Africa. Curr Opin Virol 17:138–44
Herbert AS, Kuehne AI, Barth JF, et al (2013) Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol 87(9):4952–64
Huttner A, Dayer J-A, Yerly S, et al (2015) The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomized double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 15(10):1156–66
Kugelman JR, Sanchez-Lockhart M, Andersen KG, et al (2015) Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics. MBio 6(1).pii:e02227
Madelain V, Nguyen TH, Olivo A, et al (2016) Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. Clin Pharmacokinet. 55(8):907–23.
Mahanty S, Bray M (2004) Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4(8):487–98
Martins KA, Jahrling PB, Bavari S, Kuhn JH (2016) Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines 15(9):1101–12
Meyer M, Garron T, Lubaki NM, et al (2015) Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest 125(8):3241–55
Milligan ID, Gibani MM, Sewell R, et al (2016) Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA 315(15):1610–23
Mire CE, Matassov D, Geisbert JB, et al (2015) Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature 520(7549):688–91
Ohimain EI (2016) Recent advances in the development of vaccines for Ebola virus disease. Virus Res 211:174–85
OMS (2016) Maladie à virus Ebola. Aide mémoire N°103. (En ligne] (accédé le 11 juin 2016)
Richardson JS1, Pillet S, Bello AJ, Kobinger GP (2013) Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol 87(7):3668–77
Sridhar S (2015) Clinical development of Ebola vaccines. Ther Adv Vaccines 3(5–6):125–38
Stanley DA, Honko AN, Asiedu C, et al (2014) Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 20(10):1126–9
Sullivan NJ, Sanchez A, Rollin PE, et al (2000) Development of a preventive vaccine for Ebola virus infection in primates. Nature 408(6812):605–9
Swenson DL, Warfield KL, Negley DL, et al (2005) Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23(23):3033–42
Tapia MD, Sow SO, Lyke KE, et al (2016) Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, doseescalation trial, and a nested, randomised, double-blind, placebocontrolled trial. Lancet Infect Dis 16(1):31–42
Tsuda Y, Caposio P, Parkins CJ, et al (2011) A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis 5(8):e1275
Warfield KL, Swenson DL, Demmin G, Bavari S (2005) Filovirus-like particles as vaccines and discovery tools. Expert Rev Vaccines 4(3):429–40
Warfield JL, Swenson DL, Olinger GG, et al (2007) Ebola viruslike particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196(S2):S430–7
Zhu FC, Hou LH, Li JX, et al (2015) Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 385(9984):2272–9
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Buchy, P. Aperçu des vaccins Ebola en phase clinique et préclinique de développement. Bull. Soc. Pathol. Exot. 109, 256–261 (2016). https://doi.org/10.1007/s13149-016-0521-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13149-016-0521-2
Mots clés
- Ebola
- Vaccins
- Vaccins viraux non réplicatifs
- vaccins viraux réplicatifs
- Revue
Keywords
- Ebola
- Vaccine
- Non-replicative viral vaccines
- Replicative viral vaccines
- Review